Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. (ITCI) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ITCI · as of Jun 9, 2026
Key Statistics
Explore Intra-Cellular Therapies, Inc. Data
itci stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 23 · Buy rate: 60.9%
The ITCI analyst consensus is Buy, based on ratings from 23 Wall Street analysts over the past 3 months. The average 12-month price target is $98.50, representing -25.31% downside from the current price of $131.87.
Competitors & Peers
itci competitorsITCI
ABMD
BDX
CTLT
IMGN
KRTXStock Performance
Full HistoryAbout Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting th…
what is intra-cellular therapies, inc. · itci stock overview · intra-cellular therapies, inc. company profile · who is intra-cellular therapies, inc. ceo · itci NASDAQ · intra-cellular therapies, inc. headquarters · intra-cellular therapies, inc. business segments
About Stock Overview & Key Data
Intra-Cellular Therapies, Inc. (ITCI) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Jan 7, 2014. As of the latest trading session, ITCI stock price is $131.87, with a market capitalization of $14.0B. The stock has returned +87.48% over the past 12 months and +56.54% year-to-date.
According to 23 Wall Street analysts, the consensus rating for Intra-Cellular Therapies, Inc. stock is Buy, with an average 12-month price target of $98.50. In fiscal year 2024, Intra-Cellular Therapies, Inc. reported revenue of $680.9M and net income of -$74.7M. For detailed data — including Intra-Cellular Therapies, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Intra-Cellular Therapies, Inc. (ITCI) stock price is $131.87. The stock is traded on NASDAQ under the ticker symbol ITCI. The 52-week range is $64.09 – $131.98.